2.13
price up icon0.95%   0.02
after-market アフターアワーズ: 2.13
loading
前日終値:
$2.11
開ける:
$2.13
24時間の取引高:
5.04M
Relative Volume:
0.54
時価総額:
$732.67M
収益:
$22,000
当期純損益:
$-190.89M
株価収益率:
-2.4534
EPS:
-0.8682
ネットキャッシュフロー:
$-149.63M
1週間 パフォーマンス:
-9.36%
1か月 パフォーマンス:
-4.05%
6か月 パフォーマンス:
+76.03%
1年 パフォーマンス:
+26.79%
1日の値動き範囲:
Value
$2.105
$2.175
1週間の範囲:
Value
$2.09
$2.39
52週間の値動き範囲:
Value
$0.8621
$4.46

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1105)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
152
Name
Twitter
@AllogeneTx
Name
次回の収益日
2026-05-12
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ALLO icon
ALLO
Allogene Therapeutics Inc
2.13 753.31M 22,000 -190.89M -149.63M -0.8682
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
427.38 109.41B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
707.06 76.72B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
781.72 48.20B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
309.49 40.31B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
295.27 33.13B 5.36B 287.73M 924.18M 2.5229

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-16 アップグレード JP Morgan Underweight → Neutral
2026-04-10 再開されました Jefferies Buy
2026-01-09 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-10-10 ダウングレード JP Morgan Neutral → Underweight
2025-05-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
Apr 28, 2026

Allogene Therapeutics (ALLO) price target increased by 16.66% to 8.83 - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’ - MSN

Apr 28, 2026
pulisher
Apr 27, 2026

Pfizer in deal with Allogene to develop cancer cell therapies - AOL.com

Apr 27, 2026
pulisher
Apr 27, 2026

Allogene Therapeutics stock hits 52-week highhere's why - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach - Traders Union

Apr 27, 2026
pulisher
Apr 27, 2026

Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

Allogene licensor Cellectis faces patent lawsuit in the U.S. - MSN

Apr 27, 2026
pulisher
Apr 26, 2026

JP Morgan Upgrades Allogene Therapeutics (ALLO) - MSN

Apr 26, 2026
pulisher
Apr 26, 2026

JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN

Apr 26, 2026
pulisher
Apr 26, 2026

Allogene Therapeutics prices $175M stock offering at $2 per share - MSN

Apr 26, 2026
pulisher
Apr 25, 2026

Allogene jumps on analysis of Phase 2 data for B-cell lymphoma asset cema-cel - MSN

Apr 25, 2026
pulisher
Apr 25, 2026

Allogene Therapeutics Expands Cancer Trial into South Korea and Australia - HarianBasis.co

Apr 25, 2026
pulisher
Apr 25, 2026

Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In - Yahoo Finance

Apr 25, 2026
pulisher
Apr 24, 2026

10 Best Growth Stocks Under $10 to Invest In - Insider Monkey

Apr 24, 2026
pulisher
Apr 24, 2026

Allogene Therapeutics aims to redefine CAR T therapy with scalable allogeneic approach - Traders Union

Apr 24, 2026
pulisher
Apr 24, 2026

Allogene Therapeutics announces public offering of $175M of common stock - MSN

Apr 24, 2026
pulisher
Apr 23, 2026

Allogene Therapeutics (NASDAQ:ALLO) SVP Annie Yoshiyama Sells 9,586 Shares - MarketBeat

Apr 23, 2026
pulisher
Apr 23, 2026

[SCHEDULE 13G] Allogene Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan

Apr 23, 2026
pulisher
Apr 23, 2026

Allogene (NASDAQ: ALLO) SVP sale covers RSU taxes, holds 124,517 shares - Stock Titan

Apr 23, 2026
pulisher
Apr 23, 2026

Allogene Therapeutics VP joins FiercePharmaEngage to drive M and A strategies in allogeneic cell therapy - Traders Union

Apr 23, 2026
pulisher
Apr 23, 2026

Analysts Are Bullish on Top Healthcare Stocks: Merck & Company (MRK), Allogene Therapeutics (ALLO) - The Globe and Mail

Apr 23, 2026
pulisher
Apr 23, 2026

H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics (ALLO) - Insider Monkey

Apr 23, 2026
pulisher
Apr 22, 2026

Allogene expands lymphoma trial to South Korea, Australia By Investing.com - Investing.com India

Apr 22, 2026
pulisher
Apr 22, 2026

Allogene Therapeutics Inc (ALLO) News, Articles, Events & Latest Updates - Stocktwits

Apr 22, 2026
pulisher
Apr 21, 2026

Allogene Therapeutics, Inc.Common Stock (NQ: ALLO - FinancialContent

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene (NASDAQ: ALLO) RSU vests 9,586 shares; Form 144 filed 04/21/2026 - Stock Titan

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene Therapeutics drives international momentum with ALPHA3 trial and targets Q2 2026 screening - Traders Union

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6%Should You Sell? - MarketBeat

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene Therapeutics (ALLO) Expands Groundbreaking Study in Sou - GuruFocus

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia - marketscreener.com

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene expands lymphoma trial to South Korea, Australia - Investing.com

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire

Apr 21, 2026
pulisher
Apr 21, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN

Apr 21, 2026
pulisher
Apr 20, 2026

Allogene (NASDAQ: ALLO) proxy urges approval to raise authorized shares to 800M - Stock Titan

Apr 20, 2026
pulisher
Apr 20, 2026

Latham & Watkins Advises on Allogene Therapeutics’ US$200.4 Million Public Offering of Common Stock - Legal Desire Media and Insights

Apr 20, 2026
pulisher
Apr 20, 2026

Allogene Therapeutics presents dual CAR-T cell data for high-risk myeloma after BCMA therapy - Traders Union

Apr 20, 2026
pulisher
Apr 20, 2026

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - The Manila Times

Apr 20, 2026
pulisher
Apr 18, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 18, 2026
pulisher
Apr 17, 2026

Allogene raises $200.4 million in stock offering By Investing.com - Investing.com India

Apr 17, 2026
pulisher
Apr 17, 2026

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - Sahm

Apr 17, 2026
pulisher
Apr 16, 2026

ALLO Upgraded by JP Morgan -- Rating Changed to Neutral - GuruFocus

Apr 16, 2026
pulisher
Apr 16, 2026

Allogene Therapeutics advances allogeneic CAR T interim results in early LBCL consolidation - Traders Union

Apr 16, 2026
pulisher
Apr 16, 2026

ALLO Stock Rockets As ALPHA3 CAR‑T Data Reset Expectations - timothysykes.com

Apr 16, 2026

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.53
price up icon 3.67%
$50.09
price up icon 1.21%
$103.45
price up icon 1.85%
$136.33
price up icon 0.96%
$144.12
price up icon 2.54%
ONC ONC
$295.27
price up icon 1.54%
大文字化:     |  ボリューム (24 時間):